Clinical trials: Metastases, Neoplasm
Liver Ablation, Liver Cancer
A Retrospective Registry of Intelliblate DUAL Channel Microwave Ablation
This study reviews past patient records from multiple hospitals to learn how safe and effective the IntelliBlate Microwave Ablation System is when used to treat liver tumors with two probes at the same time.
- Conditions
- Liver Ablation, Liver Cancer, Liver Cancer (Primary and Metastatic)
- Trial name
- DUAL (NCT07900984)
- Testing
- Intelliblate Microwave Ablation (MWA) System
- Volunteers
- 63 people
- Sponsor
- Varian, a Siemens Healthineers Company
Cancer, Malignancy
A Study of ASN007 in Patients With Advanced Solid Tumors
The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups.
- Conditions
- Cancer, Malignancy, Neoplasia, Neoplasm
- Trial name
- NCT03415126
- Testing
- ASN007: ascending doses, ASN007 RD
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Asana BioSciences
Neoplasms, Breast
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
This study will provide pre-approval drug access to lapatinib, in combination with capecitabine, to patients whose breast cancer had progressed on other therapies
- Trial name
- NCT00338247
- Testing
- lapatinib + capecitabine
- Where
- 453 sites in United States, Australia and 43 more
- Sponsor
- Novartis
Patients w/Advanced Cancer That Failed Std of Care Therapy
A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer
This is a single center in patient/outpatient, uncontrolled dose escalating study in cancer patients to evaluate the safety, tolerability and pharmacokinetic (PK) profiles of body surface area adjusted doses of liposomal curcumin…
- Trial name
- NCT02138955
- Testing
- Liposomeal curcumin
- Where
- 2 sites in Austria
- Volunteers
- 30 people
- Sponsor
- SignPath Pharma, Inc.
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
- Trial name
- NCT06607185
- Testing
- LY4066434., Cetuximab, Nab paclitaxel
- Where
- 45 sites in United States, Belgium and 6 more
- Volunteers
- 750 people
- Sponsor
- Eli Lilly and Company
Metastatic Castration-resistant Prostate Cancer
Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
The VIABLE study sought to confirm the hypothesis that the combination of docetaxel with DCVAC/PCa followed by a maintenance therapy with DCVAC/PCa would improve overall survival in patients with metastatic castration-resistant…
- Trial name
- VIABLE (NCT02111577)
- Testing
- DCVAC/PCa
- Where
- 177 sites in United States, Austria and 20 more
- Volunteers
- 1,182 people
- Sponsor
- SOTIO a.s.
Bone Metastasis
Feasibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases
This purpose of this study is to assess the feasibility of FLASH radiotherapy for the palliative treatment of painful bone metastases.
- Trial name
- FAST-01 (NCT04592887)
- Testing
- FLASH Radiotherapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Varian, a Siemens Healthineers Company
Non Small Cell Lung Cancer, Brain Metastases
A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy
The purpose of this study is to evaluate the efficacy of icotinib alone or in combination with radiation therapy for NSCLC patients harboring EGFR mutation with brain metastases. The primary endpoint is overall survival .
- Trial name
- SMART (NCT04058704)
- Testing
- Icotinib, SRS/WBRT/HA-WBRT/SMART
- Where
- China
- Volunteers
- 296 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Solid Tumour, Advanced Solid Malignancies
A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.
This is Phase I, open-label and dose escalation study to evaluate the safety and tolerability of AZD1480(JAK2 inhibitor) in Asian patients with advanced solid tumors (Part A and C) and in patients with advanced HCC (Part B) in…
- Conditions
- Solid Tumour, Advanced Solid Malignancies, Child-Pugh A to B7 Advanced Hepatocellular Carcinoma, EGFR and/or ROS Mutant NSCLC
- Trial name
- NCT01219543
- Testing
- AZD1480 Daily, AZD1480 BID
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Castrate Resistant Prostate Cancer With Bone Metastasis
Investigating the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) on the Treatment of Subjects With CRPC
Studies objectives: To evaluate the safety, tolerability and efficacy of ACC given in combination with ZA or with Denosumab as compared to placebo given with ZA or with Denosumab as outline below: Safety and Tolerability: Adverse…
- Trial name
- NCT02864784
- Testing
- Amorphous calcium carbonate
- Where
- Israel
- Sponsor
- Amorphical Ltd.
Liver Metastasis, Colorectal Neoplasms
Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases
The purpose of this study is to determine whether the Litx™ system is safe and effective in combination with chemotherapy in the treatment of liver metastasis arising from colorectal cancer.
- Conditions
- Liver Metastasis, Colorectal Neoplasms, Liver Neoplasms, Neoplasm Metastasis
- Trial name
- NCT00083785
- Testing
- Talaporfin sodium (LS11), LED-based light infusion device, Light emitting diodes (LED)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Light Sciences LLC
Unspecified Adult Solid Tumor, Protocol Specific
3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00016874
- Testing
- cisplatin, paclitaxel, triapine
- Where
- 2 sites in United States
- Sponsor
- Vion Pharmaceuticals
Solid Tumors
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
This study will be conducted in 5 parts (Parts A, B, C, D and E). Monotherapy Treatment: Subjects ≥18 years with advanced solid tumors will be enrolled in the study. Monotherapy dose escalation will be performed in Part A.
- Trial name
- NCT02628574
- Testing
- TRX518 monotherapy, TRX518 with gemcitabine, TRX518 with pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- Leap Therapeutics, Inc.
Thrombocytosis, Myeloproliferative Neoplasms
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders
Anagrelide is a drug that has been shown to slow down how fast platelets are made in the bone marrow, and has been approved by the FDA for treating high platelets counts in patients with bone marrow disorders.
- Trial name
- NCT02125318
- Testing
- Anagrelide CR
- Where
- 11 sites in United States
- Volunteers
- 18 people
- Sponsor
- Galena Biopharma, Inc.
Advanced Solid Tumor, Cutaneous Tumor
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed…
- Conditions
- Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor
- Trial name
- ANCHOR (NCT06171750)
- Testing
- tolododekin alfa, Cemiplimab
- Where
- 5 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- Ankyra Therapeutics, Inc
Soft Tissue Sarcoma
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
A Phase IIa open label study evaluating the preliminary efficacy of intratumoural tigilanol tiglate in advanced and/or metastatic soft tissue sarcoma of the extremities and body wall.
- Trial name
- NCT05755113
- Testing
- Tigilanol Tiglate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- QBiotics Group Limited
Hepatocellular Carcinoma
Trial of TG4023 Combined With Flucytosine in Liver Tumors
This trial is a phase I, open-label, dose-escalating study of the safety or percutaneous intra-tumoral injection of TG4023 (MVA-FCU1) combined with systemic administration of 5-fluorocytosine in patients with primary or secondary…
- Trial name
- NCT00978107
- Testing
- MVA-FCU1, flucytosine
- Where
- 6 sites in France
- Volunteers
- 16 people
- Sponsor
- Transgene
Metastatic Cancer
In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation
This is a Phase I/II study to investigate the feasibility of creating a personalized therapeutic cancer vaccine within the body. A vaccine contains a source of tumor antigen and an adjuvant.
- Trial name
- NCT00861107
- Testing
- AlloStim-7, percutaneous tumor cryoablation, AlloStim8 or AlloStim-9
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mirror Biologics, Inc.
Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
This is a clinical trial with a crossover design to determine patients' preference for capecitabine in combination with bevacizumab or everolimus in combination with exemestane for advanced breast cancer patients and to evaluate…
- Conditions
- Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast, Hormone Receptor Positive Malignant Neoplasm of Breast
- Trial name
- IMPROVE (NCT02248571)
- Testing
- Bevacizumab, Capecitabine, Everolimus
- Where
- Germany
- Volunteers
- 85 people
- Sponsor
- iOMEDICO AG
Ovarian Cancer
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer
The primary objective of this randomized phase II trial is to compare progression-free survival (PFS) in patients randomized to NGR-hTNF plus an anthracycline versus patients randomized to an anthracycline alone
- Trial name
- NGR018 (NCT01358071)
- Testing
- NGR-hTNF, Pegylated liposomal doxorubicin, Doxorubicin
- Where
- 8 sites in Italy, United Kingdom
- Volunteers
- 119 people
- Sponsor
- AGC Biologics S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.